Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.6.5.2 (NQO1)
 6,196 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

NADPH-quinone reductase catalyzes the two-electron reduction of quinones such as menadione, and generally is considered to play a protective role against quinone-mediated toxicity. Recent studies have shown that reactive oxygen intermediates may be produced during metabolism of quinones by quinone reductase. Experiments were carried out to evaluate the effect of iron complexes on production of hydroxyl radical (.OH) when menadione was oxidized by a rat liver cytosolic fraction. Menadione-stimulated H2O2 production when added to the cytosol; dicoumarol, a potent inhibitor of quinone reductase, completely blocked this stimulation. Results were identical with either NADH or NADPH as reductant. In the absence of added iron, .OH, assessed as oxidation of chemical scavengers, was not produced. Various ferric chelates, added to the cytosol in the absence of menadione, did not catalyze .OH production. However, .OH was produced in the presence of menadione with all ferric complexes evaluated except for ferric-desferrioxamine. Catalase, competitive scavengers and GSH inhibited .OH production, as did dicoumarol. Superoxide dismutase inhibited with ferric-ATP, ferric-citrate, ferric-histidine or ferric ammonium sulfate as iron catalysts, but had no effect with ferric-EDTA or ferric-diethylenetriamine penta-acetic acid. Reduction of the ferric complexes was increased by menadione. NADH and NADPH were equally effective as cofactor for all these reactions. Metabolism of menadione in the presence of iron complexes caused inactivation of enzymes present in the cytosolic fraction such as glutamine synthetase and lactic dehydrogenase. These results indicate that metabolism of menadione by quinone reductase can lead to the production of .OH in the presence of various ferric catalysts.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Requirement for iron for the production of hydroxyl radicals by rat liver quinone reductase. 769 Apr

Current conventional measurement of allantoin levels in human serum uses an HPLC method. However, performing this assay is time-consuming and sample-intensive, and it requires expensive equipment. We have developed a novel enzyme cycling method for measuring allantoin concentrations in human serum. In the first step, serum allantoin is converted to allantoate by the action of allantoinase (EC 3.5.2.5), and endogenous ammonia is simultaneously removed by the action of glutamine synthetase II (EC 6.3.1.2). In the second step, l-methionine sulfoximine is used to inhibit glutamine synthetase II, and ammonia is liberated from allantoate by the activity of allantoate amidohydrolase (EC 3.5.3.9). In the final step, the ammonia is then converted to NAD by NAD synthetase (EC 6.3.1.5). Subsequent action of glucose dehydrogenase (EC 1.1.1.47) and diaphorase (EC 1.6.99.2) in the presence of glucose and 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1) acts to cycle the formed NAD between its oxidized and reduced forms, resulting in the production of WST-1 formazan, which is monitored at 450 nm. The assay standard curve is linear from 0 to 70 muM allantoin. The level of allantoin in healthy subjects was measured to be 8.2+/-3.1 microM (n=30).
 ...
PMID:An enzyme cycling method for measurement of allantoin in human serum. 1844 70